# NMIIA/IIB inhibitor

Type: Technology

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/nmiiaiib-inhibitor
Canonical HTML page: https://gethealthbrief.com/entity/nmiiaiib-inhibitor

## Timeline

- **2026-03-24**: BioFlorida Showcase — Cornerstone Session presentation on innovation in the regional ecosystem.
- **2026-03-10**: Investival Showcase — Presentation at the South Florida Rising Life Science Hub event.
- **2026-03-09**: Conference Invitations — Announced invitations to two major South Florida life sciences showcases.
- **2026-02-15**: National Partnering — Presented at BioCom California Global Life Science Partnering Conference.

## Recent coverage (1 stories)

### Myosin Therapeutics Showcases Nanomotor Platform Amid South Florida Biotech Surge
2026-03-10 01:07:45 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Myosin Therapeutics has been selected to present its first-in-class nanomotor-dependency platform at two major South Florida life sciences conferences in March 2026. The company is advancing MT-125, a dual NMIIA/IIB inhibitor currently in Phase 1/2 trials for glioblastoma, targeting the physical mechanics of cancer cells to bypass traditional resistance.
Full story: https://gethealthbrief.com/story/myosin-therapeutics-nanomotor-oncology-briefing-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.